Publication Date:
2020-09-18
Description:
Background While chemotherapy saves lives, increasing evidence shows that chemotherapy accelerates aging. We previously demonstrated that mRNA expression of p16INK4a, a biomarker of senescence and molecular aging, increased early and dramatically after beginning adjuvant anthracycline-based regimens in early-stage breast cancer patients. Here, we determined if changes in p16INK4a expression vary by chemotherapy regimen among early-stage breast cancer patients. Methods We conducted a study of Stage I-III breast cancer patients receiving adjuvant or neoadjuvant chemotherapy. p16INK4a expression was analyzed pre-chemotherapy and post-chemotherapy (median 6.2 months after the last chemotherapy) in peripheral blood T-lymphocytes. Chemotherapy-induced change in p16INK4a expression was compared among regimens. All statistical tests were two-sided. Results In 146 women, chemotherapy was associated with a statistically significant increase in p16INK4a expression (accelerated aging of 17 years; p
Electronic ISSN:
2515-5091
Topics:
Chemistry and Pharmacology
,
Medicine
Permalink